These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 2841837

  • 1. Relative significance of dopamine receptors, beta adrenoceptors and norepinephrine uptake inhibition in the cardiovascular actions of dopexamine hydrochloride.
    Goldberg LI, Bass AS.
    Am J Cardiol; 1988 Aug 11; 62(5):37C-40C. PubMed ID: 2841837
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms mediating the positive inotropic and chronotropic changes induced by dopexamine in the anesthetized dog.
    Bass AS, Kohli JD, Lubbers N, Goldberg LI.
    J Pharmacol Exp Ther; 1987 Sep 11; 242(3):940-4. PubMed ID: 2888876
    [Abstract] [Full Text] [Related]

  • 3. Changes in cardiovascular responsiveness to dopexamine and beta 1- and beta 2-adrenoceptor function after the chronic treatment of beta-adrenoceptor antagonists and agonists in anaesthetized dogs.
    Chang DH, Einstein R.
    J Auton Pharmacol; 1996 Oct 11; 16(5):269-79. PubMed ID: 9023671
    [Abstract] [Full Text] [Related]

  • 4. [Dopexamine: a new dopaminergic agonist].
    Perrin G, Papazian L, Martin C.
    Ann Fr Anesth Reanim; 1993 Oct 11; 12(3):308-20. PubMed ID: 7902685
    [Abstract] [Full Text] [Related]

  • 5. An introduction to the pharmacologic properties of Dopacard (dopexamine hydrochloride).
    Smith GW, O'Connor SE.
    Am J Cardiol; 1988 Aug 11; 62(5):9C-17C. PubMed ID: 2900602
    [Abstract] [Full Text] [Related]

  • 6. The cardiovascular actions of dopexamine hydrochloride, an agonist at dopamine receptors and beta 2-adrenoceptors in the dog.
    Smith GW, Hall JC, Farmer JB, Simpson WT.
    J Pharm Pharmacol; 1987 Aug 11; 39(8):636-41. PubMed ID: 2888855
    [Abstract] [Full Text] [Related]

  • 7. Role of the beta 2 adrenoceptor in mediating positive inotropic activity in the failing heart and its relation to the hemodynamic actions of dopexamine hydrochloride.
    Lang RM, Borow KM, Neumann A, Carroll JD, Weinert L, Murphy MB, Ghali J, Rajfer SI.
    Am J Cardiol; 1988 Aug 11; 62(5):46C-52C. PubMed ID: 2841838
    [Abstract] [Full Text] [Related]

  • 8. Arrhythmogenic potential of dopexamine hydrochloride during halothane anaesthesia in dogs.
    Neustein SM, Dimich I, Sampson I, Sadeghi A, Mezrow C, Shiang H.
    Can J Anaesth; 1994 Jun 11; 41(6):542-6. PubMed ID: 7915210
    [Abstract] [Full Text] [Related]

  • 9. Potentiation by dopexamine of the cardiac responses to circulating and neuronally released norepinephrine: a possible mechanism for the therapeutic effects of the drug.
    Bass AS, Murphy MB, Kohli JD, Goldberg LI.
    J Cardiovasc Pharmacol; 1989 Apr 11; 13(4):667-71. PubMed ID: 2471007
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular actions of dopexamine in anaesthetized and conscious dogs.
    Einstein R, Abdul-Hussein N, Wong TW, Chang DH, Matthews R, Richardson DP.
    Br J Pharmacol; 1994 Jan 11; 111(1):199-204. PubMed ID: 7912154
    [Abstract] [Full Text] [Related]

  • 11. The effects of dopexamine on the cardiovascular system of the dog.
    Brown RA, Farmer JB, Hall JC, Humphries RG, O'Connor SE, Smith GW.
    Br J Pharmacol; 1985 Jul 11; 85(3):609-19. PubMed ID: 4027482
    [Abstract] [Full Text] [Related]

  • 12. Inotropic mechanisms of dopexamine hydrochloride in horses.
    Muir WW.
    Am J Vet Res; 1992 Aug 11; 53(8):1343-6. PubMed ID: 1354950
    [Abstract] [Full Text] [Related]

  • 13. Reduced effects of dopexamine on force of contraction in the failing human heart despite preserved beta 2-adrenoceptor subpopulation.
    Böhm M, Pieske B, Schnabel P, Schwinger R, Kemkes B, Klövekorn WP, Erdmann E.
    J Cardiovasc Pharmacol; 1989 Oct 11; 14(4):549-59. PubMed ID: 2478768
    [Abstract] [Full Text] [Related]

  • 14. Presynaptic effects of dopexamine hydrochloride in the canine kidney.
    Bass AS.
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jan 11; 345(1):33-6. PubMed ID: 1347154
    [Abstract] [Full Text] [Related]

  • 15. Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors.
    Brown RA, Dixon J, Farmer JB, Hall JC, Humphries RG, Ince F, O'Connor SE, Simpson WT, Smith GW.
    Br J Pharmacol; 1985 Jul 11; 85(3):599-608. PubMed ID: 2862944
    [Abstract] [Full Text] [Related]

  • 16. Inotropic, vascular and neuroendocrine effects of dopexamine hydrochloride and comparison with dobutamine.
    Jaski BE, Peters C.
    Am J Cardiol; 1988 Aug 11; 62(5):63C-67C. PubMed ID: 3407597
    [Abstract] [Full Text] [Related]

  • 17. Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.
    Fitton A, Benfield P.
    Drugs; 1990 Feb 11; 39(2):308-30. PubMed ID: 1970288
    [Abstract] [Full Text] [Related]

  • 18. The haemodynamic and myocardial effects of dopexamine: a new beta 2-adrenoceptor and dopaminergic agonist.
    Jaski BE, Wijns W, Foulds R, Serruys PW.
    Br J Clin Pharmacol; 1986 Apr 11; 21(4):393-400. PubMed ID: 2871852
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of Uptake1 by dopexamine hydrochloride in vitro.
    Mitchell PD, Smith GW, Wells E, West PA.
    Br J Pharmacol; 1987 Oct 11; 92(2):265-70. PubMed ID: 2890392
    [Abstract] [Full Text] [Related]

  • 20. Comparison of acute haemodynamic effects of dopexamine hydrochloride, dobutamine and sodium nitroprusside in chronic heart failure.
    Baumann G, Gutting M, Pfafferott C, Ningel K, Klein G.
    Eur Heart J; 1988 May 11; 9(5):503-12. PubMed ID: 3402466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.